ARCHIVES

New Phase III Follow-Up Data of Yervoy Trial Shows 19 Percent Survival at Four Years

This article is from The Cancer Letter archive.

Vol. 35 No. 10 | October 26, 2012

Download PDF Visit The Full Archive

Related Articles

Sixty CCOPs Could cost $16 Million; DCPC Staff Believes They Can Get It

October 10, 1986

FDA Committee Okays Leuprolide NDA, But Recommends Against Mitoxantrne, Epirubicin

April 5, 1985

Biological Modifiers Journal Objects To NEJ Policy, Says It Will OK Clinical Data Release

April 26, 1985

Clinical Trial Participants Sue Duke University, Potti, Nevins and Others for Causing Harm

September 9, 2011

“Honor Roll” Of Top Investigators Who Won’t Be Funded Because Of Cuts

March 8, 1985

Addendum to RAID

December 17, 1999